Knee replacement surgery: ConforMIS CEO Philipp Lang on custom joint replacement | Disruptors


In this episode of Disruptors, we talk to ConforMIS founder & CEO Philipp Lang about how the privately-held custom joint implant maker is set to revolutionize knee replacement surgery.

The Bedford, Mass.-based orthopedic maker, which started in 2004, has been on a roll for the past 3 years, having raised $89 million in a Series E funding round in early 2012, bringing its fund-raising collections to about $140 million since 2009.

Sign up to get our free newsletters delivered straight to your inbox

MassDevice publisher Brian Johnson sat down with Lang recently to discuss the company’s past and its future. Take us back before you founded the company in 2004, what was the genesis of the idea behind Conformis?

Philipp Lang: The genesis was that there are too many compromises today in knee replacement and in fact, in other forms of joint replacement. So if you look at how this was practiced in 2004 and how it is practiced in 2012 it has basically not changed.

So what it means for the surgeon is that every single time [a knee replacement is performed] he or she is confronted with having to find compromises on the shape of the device.

What this translates down to is issues with patient satisfaction. Patients have complaints with pain after surgery, they have difficulty walking downstairs, they have limited range of motion, they can’t get back to the same type of physical activity that they have before they have arthritis.

So that’s just a summary of some of the issues. If you look at some of the principal thoughts behind all of this was we want to correct any underlying deformities, bow knees, knocked knees so we go back to normal mechanical alignment of the joint. But then we want to recreate the anatomy that the patient had prior to developing arthritis.

No human knee has constant curvatures or constant radii every patient is different. If he can go back and recreate something close to the patient’s original anatomy corrected for deformity, you should get a much better clinical result, you should get a much better functional result. What were some of the limitations or questions you faced when you brought this idea before investors and physicians and surgeons?

PL: There were a number of key hurdles that we had to face. The first hurdle that we saw as we started out with earlier commercials looking back at 2008, was that we had historically started out with a partial knee approach. But so literally looking at the market dynamic, our initial implants could only address the 10% of the available market.

That said, the technology per se was so disruptive and the concept was so compelling that for those companies that published their data for the last three years, 12 quarters consecutively in a row, we have been on average the fastest-growing company in the entire space. But we had an intrinsic limitation in accessible market which we addressed now with introduction of iTotal initially in limited release which started in May of 2012 and we’ve done a couple of thousand surgeries in limited release working with a broad range of surgeons.

Then in September 15 we actually went into full commercial launch with what we call the iTotal G2 and now we can address the largest market segment in knee replacement and in fact in orthopedics in general.

The second major challenge that we had, and full disclosure we didn’t foresee when we started out with the company, was the scalability. Traditional manufacturing you would take a block of plastic and you would cap this with the C&C milling machine. The process that we’re using today is a process where basically a 3D printing machine lays down a layer of nylon powder, 50 or 100 microns typically and then  laser zips across that layer of nylon melts it, the next layer is being laid down, another layer is being melted. So in additive fashion layer by layer is being added.

What you get out of this is ultimately a disposable instrument that you see here that’s generated with an additive manufacturing 3D printing. That was manufactured in this fashion.

The fact that this new technology is available now for manufacturing that was key to our scale-up and that’s really what supports and sustains our scale-up so we have really across all manufacturing functions we have basically a cellular manufacturing approach where we look at our quarterly or 6 months forecast we look how we’re growing. We know the capacity that we can get out of one existing machine we’re just adding machines as we grow.

MassDevice: How is Conformis’ customized implant different from the current standard of care with knee replacement surgery?

PL: Well technology is different in that every knee is customized there is no more compromise, there is no over-sizing, there is no under-hang. If you look at this for example, and there is one more and we’re looking at it from the back, you can see that this medial condyle the inside of the knee is very wide while the lateral condyle is very narrow. If I had a standard implant, I would likely be two small medially and I would overhand laterally in this area causing soft tissue impingement and pain.

So those compromises are addressed comprehensively they don’t happen anymore. I think the other key compromise that we know the surgeon has to do with every single surgery is he is putting in my right hand a standard implant, he is putting a perfectly symmetrical implant into a highly asymmetrical joint. What’s the result? The result shows for the surgeon intraoperatively that the surgeon has difficulty to make the ligaments of the patient work and he does, probably has to go through a process called ligament balancing. Which means he has to cut ligaments, he has to cut soft tissue. The joint doesn’t give you enough flections or he cuts more soft tissue trying to get more flection. And he will never get the type of motion that the patient had prior to the surgery.

And what is very impressive is that when you look at the primary data at 6 weeks after surgery, close to 70 percent of patients report back that the knee feels natural they can’t tell a difference to the un-operated knee. When you look at them one year after surgery 85 percent of patients report they can’t tell the difference and that’s really unprecedented. We have very similar feedback on the iTotal where again we have less experience because we’ve just started on the limited release in May of last year. But again we’ve done a couple of thousand procedures. But we have that type of feedback.

In summary, when we look at knee replacement and today using standard devices, the patient is being fitted to the implant. What we do we take each individual patient and we fit the implant individually to the patient and that’s truly unique.

RSS From Medical Design & Outsourcing

  • Molex delivers ISO 13485-compliant, medical-grade surgical cables from its class 100,000 clean room facility
    Molex, LLC operates a fully ISO 146441-1:1999 Class 8-certified clean room, satisfying strict particulate contamination levels specified by ISO-compliant requirements. Located in Thailand, the facility has less than 100,000 particulates (≥0.5µm) per cubic foot of air and manufactures a variety of ISO 13485-compliant medical cables and surgical cables used in operating theatres, hospitals, laboratories and […]
  • Swept-Source OCT: Patent license agreement between Massachusetts General Hospital and Heidelberg Engineering
    Heidelberg Engineering has entered into a patent license agreement with Massachusetts General Hospital (MGH) in Boston. The agreement grants global and exclusive rights to 77 basic patents and patent applications which relate to swept-source OCT technology and its application in ophthalmology. Spectral domain OCT has become indispensable to eye care professionals worldwide to diagnose and […]
  • MIT’s MultiFab presents a stark challenge to incumbent 3D Printer manufacturers’ hardware, software, and business Models
    MIT’s Computational Fabrication Group recently announced the MultiFab, a low-cost 3D printer that can combine up to 10 different resins in one part and also includes a 3D scanning system to identify and fix errors during production. According to Lux Research, these capabilities are rare in commercial 3D printers today due to the manufacturers’ need […]
  • AVX releases Accu-P MP medical grade film chip capacitors for medical devices
    AVX Corporation, a leading manufacturer of passive components and interconnect solutions, has released a new series of thin film chip capacitors specifically designed to meet the demanding performance specifications for implantable medical devices. Delivering extremely tight capacitive tolerances, exceptionally repeatable performance, and remarkably low ESR and high Q at high frequencies—including VHF, UHF, and RF […]
  • RIVANNA commences manufacturing of its Accuro device
    Rivanna Medical announced that it has begun manufacturing its FDA-cleared Accuro device, a handheld and untethered smart-phone-sized device that is designed to guide spinal anesthesia with automated 3D navigation technology in addition to ultrasound imaging of abdominal, musculoskeletal, cardiac and peripheral vascular anatomies. The product will be launched at the ASA annual meeting in San […]
  • FDA seeks public input on Quality Metrics guidance
    by Oliver Wolf, Senior Product Manager, MasterControl In line with the general shift towards risk-driven approaches in the quality management world, FDA is now taking steps towards applying those same principles to its own auditing schedule. At the end of July, the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation […]
  • First ‘Ear Wear’ for Active Adults Debuts with MDHearingAid FIT
    If you’ve burned out your ears with earbuds, headphones or decades of other audio abuse but aren’t ready for your grandmother’s hearing aids, not to worry! The new MDHearingAid FIT gets you back in the game with a tiny, FDA-registered, one-size-fits-most solution that doesn’t block your ear canal like old-fashioned in-the-ear hearing aids. The FIT feels […]
  • CardioGenics enters into manufacturing agreement with Ontario-based Plasticap
    CardioGenics Holdings, developer for the In-Vitro-Diagnostics (“IVD”) testing market, announced that it has entered into a manufacturing agreement with Plasticap of Ontario, Canada, pursuant to which Plasticap will manufacture CardioGenics’ proprietary self-metering cartridges for its QL Care analyzer. The term of the agreement is three years and the purchase price for each cartridge shall be […]
  • MTD Micro Molding releases micro materials menu
    MTD Micro Molding, a long-time leader in micro-injection molding, has released an updated “Materials Menu” of materials that can be successfully micromolded to help guide engineers at medical device companies. Material selection is a crucial step in product manufacturability. The correct material drives tolerance, dimension, strength, usabality, speed-to-market, design, critical features, and cost. Through MTD’s […]
  • MedTech Chat: Elastic technology for drug delivery
    Dr. Zhen Gu and Dr. Yong Zhu from North Carolina State University are both co-senior authors of a research paper describing their recent work. Dr. Gu, Dr. Zhu and other researchers from North Carolina State University and the University of North Carolina at Chapel Hill have developed a drug delivery technology that consists of an […]
  • B. Braun’s OEM Division offers large bore normally closed low-pressure check valves
    Infusion therapy and pain management device manufacturer B. Braun said today it is offering normally closed large-bore low-pressure check valves through its valve-focused contract manufacturing OEM division. The valves, offered by Bethlehem, Pa.-based B. Braun, are designed for the intermittent injection of fluids during medical treatment and open automatically when pressure is applied. The newly […]

Leave a Reply